Literature DB >> 14642972

Muscarinic mechanisms of antipsychotic atypicality.

Frank P Bymaster1, Christian C Felder, Eleni Tzavara, George G Nomikos, David O Calligaro, David L Mckinzie.   

Abstract

The interactions of the atypical antipsychotic drugs (APD) clozapine, olanzapine, risperidone, quetiapine and ziprasidone with muscarinic receptors were reviewed. Only clozapine and olanzapine have marked affinity for muscarinic receptors in radioligand binding studies; however, the affinity of these compounds is considerably lower than classical muscarinic antagonists. Although functional assays in cell lines transfected with muscarinic receptors suggest that olanzapine and clozapine have weak partial agonist activity at muscarinic receptors, particularly M4 receptors, studies in vitro and in vivo indicate that the compounds function as antagonists. In animal studies and in humans, clozapine has pronounced antimuscarinic effects whereas olanzapine has weak antimuscarinic effects. However, olanzapine significantly occupies central muscarinic receptors in humans. Overall, the role of muscarinic receptors in the antipsychotic effects of clozapine and olanzapine is controversial and complex.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642972     DOI: 10.1016/j.pnpbp.2003.09.008

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  41 in total

Review 1.  Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Authors:  Gregory J Digby; Jana K Shirey; P Jeffrey Conn
Journal:  Mol Biosyst       Date:  2010-06-25

Review 2.  The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.

Authors:  Holly Moore
Journal:  Schizophr Bull       Date:  2010-09-24       Impact factor: 9.306

Review 3.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

4.  Regulation of synaptic plasticity in a schizophrenia model.

Authors:  Barbara Gisabella; Vadim Y Bolshakov; Francine M Benes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-30       Impact factor: 11.205

Review 5.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning.

Authors:  Douglas J Sheffler; Richard Williams; Thomas M Bridges; Zixiu Xiang; Alexander S Kane; Nellie E Byun; Satyawan Jadhav; Mathew M Mock; Fang Zheng; L Michelle Lewis; Carrie K Jones; Colleen M Niswender; Charles D Weaver; Craig W Lindsley; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2009-04-30       Impact factor: 4.436

Review 7.  Classifying antipsychotic agents : need for new terminology.

Authors:  Ripu D Jindal; Matcheri S Keshavan
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

9.  Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats.

Authors:  A V Terry; S E Warner; L Vandenhuerk; A Pillai; S P Mahadik; G Zhang; M G Bartlett
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

10.  Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.

Authors:  Morgane Thomsen; Jürgen Wess; Brian S Fulton; Anders Fink-Jensen; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.